A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia

June 1, 2016

Authors: Claudia Trenkwalder, Daniela Berg, Olivier Rascol, Karla Eggert, Andres Ceballos-Baumann, Jean-Christophe Corvol, Alexander Storch, Lin Zhang, Jean-Philippe Azulay, Emmanuel Broussolle, Luc Defebvre, Christian Geny, Michal Gostkowski, Fabrizio Stocchi, Christine Tranchant, Pascal Derkinderen, Franck Durif, Alberto J Espay, Andrew Feigin, Jean-Luc Houeto, Johannes Schwarz, Thérèse Di Paolo, Dominik Feuerbach, Hans-Ulrich Hockey, Judith Jaeger, Annamaria Jakab, Donald Johns, Gurutz Linazasoro, Paul Maruff, Izabela Rozenberg, Judit Sovago, Markus Weiss, Baltazar Gomez-Mancilla

Journal: Movement Disorders

DOI: 10.1002/mds.26569

Year Published: 2016


This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson’s disease and levodopa-induced dyskinesia.


Patients with idiopathic Parkinson’s disease and moderate to severe levodopa-induced dyskinesia were randomized to AQW051 10 mg (n = 24), AQW051 50 mg (n = 24), or placebo (n = 23) once daily for 28 days. Coprimary end points were change in Modified Abnormal Involuntary Movement Scale and Unified Parkinson’s Disease Rating Scale part III scores. Secondary outcomes included pharmacokinetics.


In total, 67 patients completed the study. AQW051-treated patients experienced no significant improvements in Modified Abnormal Involuntary Movement Scale or Unified Parkinson’s Disease Rating Scale part III scores by day 28. AQW051 was well tolerated; the most common adverse events were dyskinesia, fatigue, nausea, and falls.


AQW051 did not significantly reduce dyskinesia or parkinsonian severity. © 2016 International Parkinson and Movement Disorder Society.

Back to Publications